1. 2096 Phase II trial of Irinotecan plus S-1 (IRIS) with Cetuximab (IRIS/Cet) in pre-treated patients with KRAS wild type of metastatic colorectal cancer (mCRC): HGCSG0902 updated analysis. (September 2015) Authors: Nakamura, M.; Yuki, S.; Nakatsumi, H.; Muto, O.; Hosokawa, A.; Kato, T.; Iwanaga, I.; Hatanaka, K.; Tsuji, Y.; Sato, A.; Eto, K.; Furukawa, K.; Okuda, H.; Onodera, M.; Fujikawa, K.; Kudo, M.; Yokoyama, S.; Honda, T.; Sakata, Y.; Komatsu, Y. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S360 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 2099 Association of morphologic response with overall survival in patients with metastatic colorectal cancer treated with bevacizumab-based chemotherapy: Updated analysis - HGCSG0802. (September 2015) Authors: Yagisawa, M.; Yuki, S.; Muranaka, T.; Sawada, K.; Hatanaka, K.; Kato, T.; Meguro, T.; Nakamura, M.; Iwanaga, I.; Eto, K.; Sato, A.; Okuda, H.; Kato, K.; Miyagishima, T.; Muto, O.; Yabusaki, S.; Miyamoto, N.; Kudo, K.; Sakata, Y.; Komatsu, Y. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S361 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗